Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Conclusions: Performance status, number of metastatic organs, and response to crizotinib affected PFS of crizotinib in ALK-positive NSCLC. Based on these factors, we developed a simple and useful prediction model for PFS.
PMID: 29950554 [PubMed - as supplied by publisher]
Source: The Korean Journal of Internal Medicine - Category: Internal Medicine Authors: Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS Tags: Korean J Intern Med Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Internal Medicine | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Study | Training | Universities & Medical Training